# Tenecteplase in Stroke Patients Between 4.5 and 24 Hours

> **NCT03785678** · PHASE3 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 458 (actual)

## Conditions studied

- THROMBOLYSIS

## Interventions

- **BIOLOGICAL:** Tenecteplase
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03785678
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-02
- **Primary completion:** 2023-02-28
- **Final completion:** 2023-02-28
- **Target enrollment:** 458 (ACTUAL)
- **Last updated:** 2024-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03785678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03785678, "Tenecteplase in Stroke Patients Between 4.5 and 24 Hours". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03785678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*